Mark J Rosenblum bought $16k of DCOY
Exec VP Finance, CFO at Salarius Pharmaceuticals, Inc.. 20,000 shares at an average of $0.80, traded Nov 20, 2025, filed Nov 20, 2025.
Score components
- +22RoleCFO
- 0Trade size$16k at market
- +10Relative to holdingsHoldings up 11299%
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -8.7%, 3m +6.4%, 6m -28.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001615219-25-000177, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 20, 2025 | POpen-market purchase Common Stock | +20,000 | $0.80 | $16k | 20,177 | Nov 20, 2025 |
Related signals
Other insiders at Salarius Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | DCOYsell Salarius Pharmaceuticals, Inc. | Arnold C Hanish director | $17 27 shares | -1% | |
| 33Weak | Salarius Pharmaceuticals, Inc. | Arnold C Hanish director | $3,741 5,000 shares | first purchase |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.